Latest News-I-Mab Mediaroom_Page

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

GAITHERSBURG, Md. and SHANGHAI, China, March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq...

2023-03-20 20:00 1815

MSCI ESG Updated I-Mab to "A" Rating

GAITHERSBURG, MD. and SHANGHAI, March 7, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2023-03-07 21:02 1591

I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022

GAITHERSBURG, MD. and SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2022-11-03 21:01 2049

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

GAITHERSBURG, Md. and SHANGHAI, Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2022-09-13 20:00 2053

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

* Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patient...

2022-09-10 21:00 1738

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022

* Seven key clinical milestones achieved year-to-date, including positive data readouts for lemzo...

2022-08-30 18:00 2101

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022

I-Mab Announces Share Purchase Plans by the Company and the Senior Management

GAITHERSBURG, Md. and SHANGHAI, Aug. 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nas...

2022-08-23 21:13 3117

I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022

- Major updates will focus on global clinical development of core assets, upcoming milestones and ...

2022-08-19 21:00 2009

I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

GAITHERSBURG, Md. and SHANGHAI, July 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2022-07-18 20:00 1587

I-Mab to Host 2022 R&D Day

GAITHERSBURG, MD. and SHANGHAI, July 6, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasd...

2022-07-06 20:00 1423

I-Mab Receives Top Rankings in Five Categories by Institutional Investor

GAITHERSBURG, Md. and SHANGHAI, June 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nas...

2022-06-23 20:00 1364

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210

SHANGHAI and GAITHERSBURG, Md., June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2022-06-15 22:37 2374

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency

SHANGHAI and GAITHERSBURG, Md., May 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2022-05-31 20:00 1484

Latest News

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

MSCI ESG Updated I-Mab to "A" Rating

I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022

I-Mab Announces Share Purchase Plans by the Company and the Senior Management

I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022

I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

I-Mab to Host 2022 R&D Day

I-Mab Receives Top Rankings in Five Categories by Institutional Investor

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act

I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer

I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021

I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022